Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Dynamic Contrast-Enhanced Magnetic Resonance Imaging is a medical procedure with 47 clinical trials. Currently 4 active trials ongoing. Historical success rate of 58.3%.
Success Metrics
Based on 21 completed trials
Phase Distribution
Phase Distribution
12
Early Stage
10
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
51.2%
21 of 41 finished
48.8%
20 ended early
4
trials recruiting
47
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer
Quantitative MRI Assessment of Breast Cancer Therapy Response
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body
Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases
DCE MRI in Patients With Pancreatic Cancer
Clinical Trials (47)
DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer
Quantitative MRI Assessment of Breast Cancer Therapy Response
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body
Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases
DCE MRI in Patients With Pancreatic Cancer
3-Tesla MRI in Finding Tumors in Patients With Known or Suspected Prostate Cancer
BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy
Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Breast MRI in Women With Known or Suspected Breast Cancer and in Healthy Participants
FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors
MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors
DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors
Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
QSM and Regional DCE MRI Permeability Using GOCART Technique
Dynamic Contrast Enhanced Magnetic Resonance Perfusion Imaging in Congenital Heart Disease and Lung Disease
Drug Details
- Intervention Type
- PROCEDURE
- Total Trials
- 47